CIRM CEO Mills On California's Last $800m For Stem Cells
This article was originally published in Scrip
Randal Mills left Osiris Therapeutics a few years after the company won the first-ever approval for a stem cell therapy and wasn't sure where he'd go next, but Mills ended up moving across the country to help California's stem cell research funding agency decide how best to spend its last $800m.
You may also be interested in...
Canaan raised $800m for tech and health care investments. Also, six companies closed VC rounds, CARB-X backed more antibiotics, CIRM funded BrainStorm and Sarepta led recent offerings.
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.
Nuvation started in 2018 and raised a $275m series A round in 2019. Now it is merging with the EcoR1 Capital-sponsored SPAC Panacea Acquisition Corp. and raising $500m in equity capital.